Project Grant R01HL179799
Award Date 8/18/26
Completion Date 4/30/30
Dollars Obligated $779K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27708, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $741,473 on June 15, 2026, to investigate the molecular mechanisms of diastolic dysfunction in heart failure with preserved ejection fraction (HFPEF). The research examines how impaired nitric oxide synthase and phosphodiesterase regulation disrupt local cyclic nucleotide signaling at the sarcoplasmic reticulum and myofilament, leading to abnormal calcium cycling and myofilament relaxation that...
- The National Heart, Lung, and Blood Institute awarded The Johns Hopkins University $248,919 in a Project Grant (CFDA 93.837, Cardiovascular Diseases Research) on June 1, 2026, to investigate skeletal muscle metabolism and exercise intolerance in heart failure patients with preserved ejection fraction (HFPEF). The award funds research using phosphorus magnetic resonance spectroscopy and magnetic resonance imaging to simultaneously measure muscle metabolism and peripheral blood flow in HFPEF...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1.272968 million on September 9, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-dependent regulation of cardiac cyclic AMP, excitation-contraction coupling, and arrhythmia by phosphodiesterases. The research addresses autonomic dysregulation and aberrant intracellular signaling in both heart failure with reduced ejection fraction and heart failure with...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $242,250 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for August 31, 2027. This feasibility study (R03 mechanism) implements arteriovenous blood sampling techniques to measure regional metabolic changes in the heart and legs during submaximal exercise...
- The National Heart, Lung, and Blood Institute awarded Massachusetts General Hospital $747,256 under Cardiovascular Diseases Research (CFDA 93.837) on August 17, 2026, to investigate the role of METTL3 (a methyltransferase enzyme) in heart failure with preserved ejection fraction (HFpEF). The project addresses an unmet clinical need: no pharmacological therapy has been proven to improve survival in HFpEF, the most prevalent form of heart failure particularly among patients with metabolic...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute awarded the University of Texas Southwestern Medical Center $811,633 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of endotrophin in heart failure with preserved ejection fraction. The recipient will conduct basic and translational research examining endotrophin (ETP), a bioactive cleavage product of collagen VI, as a molecular driver of heart failure with preserved ejection fraction...
- The National Heart, Lung, and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded The Johns Hopkins University $248,999 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate reduced hypusination of EIF5A as a mechanism of heart failure with preserved ejection fraction (HFPEF). The research addresses mechanisms underlying HFPEF, which affects over half of heart failure patients but...
- The National Heart, Lung, and Blood Institute awarded Duke University $100,228 on December 26, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop engineered innervated human heart tissues for in vitro studies of cardiac injury response. The recipient will develop and characterize a compartmentalized three-dimensional coculture model of human cardiobundles—engineered cardiac tissues derived from human induced pluripotent stem cells—innervated with sympathetic...
- The National Heart Lung and Blood Institute awarded The Johns Hopkins University $638,176 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate thrombospondin-1 (TSP-1) as a therapeutic target in heart failure with preserved ejection fraction (HFPEF). The research focuses on identifying sex-specific mechanisms underlying cardiac structural changes in HFPEF, with specific emphasis on TSP-1's role as a matricellular protein that modulates TGF-β signaling...